3-亚甲基-2-己酮 | 25409-10-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-亚甲基-2-己酮
• 英文名称: 3-propyl-3-buten-2-one
• 英文别名: 3-propyl-but-3-en-2-one；3-Propyl-but-3-en-2-on；3-methylene-2-hexanone；3-methylidenehexan-2-one
• CAS: 25409-10-3
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: FCGJAWIYGRHEAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914190090

反应信息

• 作为反应物：
  描述：

  3-亚甲基-2-己酮 反应 1.5h， 生成
  参考文献：
  名称：

  Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s

  摘要：

  The 2R*,11bS* and 2S*,11bS* diastereoisomers of the spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2, 5'-oxazolidin-2'-one] system were prepared by stereoselective methods. Evaluation of these compounds for antihypertensive activity by oral administration to the spontaneously hypertensive rat showed the 2S*,11bS* series was the more potent. Within that series it was found that small alkyl substituents at positions 3 and 4' enhanced antihypertensive activity and that methoxyl substitution at positions 9 and 10 was optimal. (2S,3S,11bS)-Spiro-[2-ethyl-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one] [(-)-9e] was one of the most efficacious compounds of this series, while its antipode, (+)-9e, was inactive. Selected compounds in this series were shown to be alpha-adrenoceptor antagonists.

  DOI：

  10.1021/jm00364a013
• 作为产物：
  描述：

  3-甲基-1-己炔-3-醇 在 二氧化碳 、 aluminium silicate 作用下， 生成 3-亚甲基-2-己酮
  参考文献：
  名称：

  Faworskaja; Fedorowa, Zhurnal Obshchei Khimii, 1951, vol. 21, p. 635,638; engl. Ausg. S. 701, 704

  摘要：

  DOI：

文献信息

• 1-Substituted-1-oxo-prostane-derivatives of the E, A and F series
  申请人：American Cyanamid Company

  公开号：US04297516A1

  公开（公告）日：1981-10-27

  The invention disclosed herein relates to pharmacologically active prostaglandin derivatives of the E, F, or A series having on the terminal methylene carbon of the alpha chain, a substituent selected from the group consisting of: ##STR1## wherein R is C.sub.1 to C.sub.6 alkyl, and phenyl or phenyl substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, OR.sub.16, SR.sub.16, F, or Cl, and R.sub.16 is C.sub.1 to C.sub.6 alkyl.

  本发明公开的药物活性前列腺素衍生物属于E、F或A系列，在α链的末端亚甲基碳上有一个取代基，该取代基从以下组中选择：##STR1## 其中R是C.sub.1至C.sub.6烷基，和苯基或苯基，苯基上带有1个或多个取代基，该取代基从以下组中选择：C.sub.1-C.sub.4烷基，OR.sub.16，SR.sub.16，F或Cl，R.sub.16是C.sub.1至C.sub.6烷基。
• 1-Hydroxymethyl-1-oxo-prostane-derivatives of the E, A and F-series
  申请人：American Cyanamid Company

  公开号：US04254036A1

  公开（公告）日：1981-03-03

  The invention disclosed herein relates to pharmacologically active prostaglandin derivatives of the E, F, or A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of: ##STR1## wherein R is an alkyl group and R.sub.15 is C.sub.1 -C.sub.4 alkyl, di-C.sub.1 -C.sub.4 -alkylamino, C.sub.1 -C.sub.4 alkoxy, and phenyl or phenyl substituted with one or more substituents from the group consisting of C.sub.1 -C.sub.4, OR, SR, F, or Cl wherein R is as previously defined.

  本发明涉及具有在α链的末端亚甲基碳上选择自以下组成的取代基的E、F或A系列药理活性前列腺素衍生物：##STR1##其中R是烷基基团，R.sub.15是C.sub.1 -C.sub.4烷基，二C.sub.1 -C.sub.4-烷基氨基，C.sub.1 -C.sub.4烷氧基，苯基或苯基，其上取代基来自C.sub.1 -C.sub.4，OR，SR，F或Cl的组成，其中R如前所定义。
• Cascade Michael Addition/Cycloketalization of Cyclic 1,3-Dicarbonyl Compounds: Important Role of the Tethered Alcohol of α,β-Unsaturated Carbonyl Compounds on Reaction Rate and Regioselectivity
  作者：Hongliang Yao、Liyan Song、Yuan Liu、Rongbiao Tong

  DOI：10.1021/jo501604e

  日期：2014.9.19

  Reactions of α,β-unsaturated aldehydes and cyclic 1,3-dicarbonyl compounds proceed primarily by cascade Knoevenagel condensation/six-π-electron electrocyclization (K6EC, formal [3 + 3] cycloaddition), while α,β-unsaturated ketones usually react with cyclic 1,3-dicarbonyl compounds in a 1,4-addition manner. This paper discloses our findings that under acidic conditions, α,β-unsaturated carbonyl compounds

  α，β-不饱和醛与环状1,3-二羰基化合物的反应主要通过Knoevenagel缩合/六-π-电子电环化（K6EC，正式的[3 + 3]环加成反应）进行，而α，β-不饱和酮通常会发生反应以1，4-加成方式与环状1，3-二羰基化合物反应。本文揭示了我们的发现，即在酸性条件下，α，β-不饱和羰基化合物（酮和醛）与束缚醇通过原位生成环己烯酮，以高度区域选择性的1,4-加成方式与环状1,3-二羰基化合物反应。假设的α-亚甲基环状氧鎓离子作为反应性迈克尔受体。我们的研究发现了束缚醇对反应速率和/或效率的重要影响，以及级联迈克尔加成/环缩酮化的一些新机理。最后，
• (3,4-DICHLORO-PHENYL)-((S)-3-PROPYL-PYRROLIDIN-3-YL)-METHANONE HYDROCHLORIDE AND MANUFACTURING PROCESSES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150045408A1

  公开（公告）日：2015-02-12

  The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates The compounds of formula I and the corresponding hydrates are pharmaceutically active substances.

  本发明涉及一种制备化合物I及其水合物的新颖方法。化合物I的公式及相应的水合物是药用活性物质。
• 15-Deoxy-16-hydroxy-17-methylene prostaglandins of the E and F series
  申请人：American Cyanamid Company

  公开号：US04232166A1

  公开（公告）日：1980-11-04

  The invention disclosed herein relates to pharmacologically active prostaglandin derivatives of the E and F series wherein C-16 is substituted with hydroxy and methyl and a double bond is introduced between C-19 and C-20. These compounds are active as bronchodilators, anti-ulcer agents and fertility control agents.

  本发明涉及药理活性的E和F系列前列腺素衍生物，其中C-16被羟基和甲基取代，并在C-19和C-20之间引入了双键。这些化合物可作为支气管扩张剂、抗溃疡剂和生育控制剂。